Latest Degarelix Stories
LOS ANGELES, Jan.
MarketResearchReports.Biz announces addition of new report “Prostate Cancer Therapeutics Market to 2019 ” to its database.
Do you or someone you know suffer from advanced prostate cancer (CRPC)? A new treatment may be available that can help treat the deadly disease.
Men experience a marked drop in their testosterone levels when taking a targeted therapy to control a specific type of lung cancer.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study.
Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug.
- A political dynamiter.